<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01298258</url>
  </required_header>
  <id_info>
    <org_study_id>99NSC-REVAC</org_study_id>
    <nct_id>NCT01298258</nct_id>
  </id_info>
  <brief_title>Significance of Regional Ventriculo-arterial Coupling in Patients With Chronic Heart Failure</brief_title>
  <official_title>Significance of Regional Ventriculo-arterial Coupling in Patients With Chronic Heart Failure: Effects of Endothelial Progenitor Cells and a Direct Renin Inhibitor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taipei Veterans General Hospital, Taiwan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Taipei Veterans General Hospital, Taiwan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators hypothesize that the different components of arterial load are coupled with&#xD;
      different components of LV function. The regional ventriculo-arterial couplings may be&#xD;
      important in the pathogenesis of heart failure and ventricular remodeling, and in the&#xD;
      prediction of future cardiovascular events.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Heart failure is a major health problem worldwide. Optimal treatment of this disabling and&#xD;
      fatal condition may require functional characterization of the failed left ventricle (LV) and&#xD;
      its interaction with the arterial system. Part of the physiological significance of the&#xD;
      ventriculo-arterial coupling has been studied experimentally and clinically using the&#xD;
      framework of the ratio of effective arterial elastance (Ea) to end-systolic elastance (Ees),&#xD;
      with limited clinical applications.&#xD;
&#xD;
      From central ascending aorta to terminal arterioles, every segment of the arterial tree&#xD;
      contributes to the arterial loads that interact and impact LV performance in both systole and&#xD;
      diastole, leads to atrial and ventricular remodeling and hypertrophy, and results in the&#xD;
      development of heart failure. On the other hand, the ventricular systole is a complex&#xD;
      coordination of multi-directional myocardial fibers involving longitudinal contraction,&#xD;
      circumferential shortening, radial thickening, twist, and torsion, the so-called LV&#xD;
      deformations.&#xD;
&#xD;
      In the proposed 3-year project, the investigators hypothesize that the different components&#xD;
      of arterial load are coupled with different components of LV function. The regional&#xD;
      ventriculo-arterial couplings may be important in the pathogenesis of heart failure and&#xD;
      ventricular remodeling, and in the prediction of future cardiovascular events. Therapies&#xD;
      targeting these may play a role in the prevention and treatment of heart failure. Therefore,&#xD;
      the investigators will study at least 60 patients with chronic heart failure (NYHA Class&#xD;
      II-IV) who will randomly receive a direct renin inhibitor, aliskiren, or a placebo for 6&#xD;
      months on top of standard therapy. The purposes of the present study are to investigate the&#xD;
      relationship between different components of hemodynamic load or arterial abnormalities and&#xD;
      different components of LV myocardial deformations or regional LV function, the modulating&#xD;
      effects of endothelial progenitor cells (EPCs) on the ventriculo-arterial coupling, and the&#xD;
      therapeutic effects of aliskiren on the components of hemodynamic load and LV myocardial&#xD;
      deformations and their couplings. The investigators will also investigate whether the&#xD;
      ventriculo-arterial coupling, EPCs, and add-on therapy of aliskiren predict cardiovascular&#xD;
      outcomes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2010</start_date>
  <completion_date type="Anticipated">July 2013</completion_date>
  <primary_completion_date type="Anticipated">July 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CV mortality and HF re-admission</measure>
    <time_frame>1 year after enrollment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ventricular function</measure>
    <time_frame>1 year after enrollment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>control group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aliskiren</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aliskiren 150 mh</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aliskiren</intervention_name>
    <description>Aliskiren 150mg</description>
    <arm_group_label>Aliskiren</arm_group_label>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Outpatients ≥ 18 years of age, male or female. Female patients must be either&#xD;
             post-menopausal for one year, surgically sterile, or using effective contraceptive&#xD;
             methods such as oral contraceptives, barrier method with spermicide or an intrauterine&#xD;
             device.&#xD;
&#xD;
          2. Patients with a diagnosis of chronic heart failure (NYHA Class II-IV) and reduced&#xD;
             systolic function: LVEF ≤ 45% at Visit 1 (local measurement, measured within the past&#xD;
             6 months assessed by echocardiogram, MUGA, CT scan, MRI or ventricular angiography).&#xD;
&#xD;
          3. NT-pro BNP ≥ 600pg/ml (BNP ≥ 150 pg/ml) at Visit 1 or NT-pro BNP ≥ 450 pg/mL (BNP (≥&#xD;
             100 pg/ml) and a hospitalization for HF within last 12 months&#xD;
&#xD;
          4. Patients must be on a stable dose of either an ACE inhibitor or an ARB for at least 4&#xD;
             weeks prior to Visit 1.&#xD;
&#xD;
          5. Patients must be treated with a beta blocker, unless contraindicated or not tolerated,&#xD;
             at a stable dose for at least 4 weeks prior to Visit 1.&#xD;
&#xD;
          6. Patients with documented sinus rhythm at Visit 1.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of hypersensitivity to any of the study drugs.&#xD;
&#xD;
          2. Patients who require treatment with both ACEI and ARB.&#xD;
&#xD;
          3. Current acute decompensated HF (exacerbation of chronic HF manifested by signs &amp;&#xD;
             symptoms that may require IV therapy).&#xD;
&#xD;
          4. Symptomatic hypotension and/or less than 100 mmHg at the time of screening or less&#xD;
             than 90 mmHg at the time of randomization.&#xD;
&#xD;
          5. eGFR &lt; 30 ml/min/1.73m2 as measured by the MDRD formula at Visit 1 (screening) , or a&#xD;
             &gt; 25% decrease after 14 days of active run-in period.&#xD;
&#xD;
          6. Serum potassium &gt; 5.0 mmol/L at screening (Visit 1).&#xD;
&#xD;
          7. Acute coronary syndrome, stroke, transient ischemic attack, cardiac, carotid or major&#xD;
             vascular surgery, percutaneous coronary intervention (PCI) or carotid angioplasty,&#xD;
             within the past 3 months prior to visit 1.&#xD;
&#xD;
          8. Coronary or carotid artery disease likely to require surgical or percutaneous&#xD;
             intervention within the 6 months after Visit 1.&#xD;
&#xD;
          9. Patients with active or unstable bronchospasm or asthma (patients must be on stable&#xD;
             regimen of respiratory medications for 1 month prior to Visit 1).&#xD;
&#xD;
         10. Right heart failure due to severe pulmonary disease.&#xD;
&#xD;
         11. Diagnosis of peripartum or chemotherapy induced cardiomyopathy within the 12 months&#xD;
             prior to visit 1.&#xD;
&#xD;
         12. Patients with a history of heart transplant or who are on a transplant list or with&#xD;
             left ventricular assistance device (LVAD device).&#xD;
&#xD;
         13. Documented ventricular arrhythmia with syncopal episodes within past 3 months, prior&#xD;
             to visit 1, that is untreated.&#xD;
&#xD;
         14. Symptomatic bradycardia or second or third degree heart block without a pacemaker.&#xD;
&#xD;
         15. Implantation of a CRT (cardiac resynchronization therapy) device within the prior 3&#xD;
             months from visit 1 or intent to implant a CRT device.&#xD;
&#xD;
         16. Presence of hemodynamically significant mitral and/or aortic valve disease, except&#xD;
             mitral regurgitation secondary to left ventricular dilatation.&#xD;
&#xD;
         17. Presence of other hemodynamically significant obstructive lesions of left ventricular&#xD;
             outflow tract, including aortic and sub-aortic stenosis.&#xD;
&#xD;
         18. Severe primary pulmonary, renal or hepatic disease.&#xD;
&#xD;
         19. Presence of any other disease with a life expectancy of &lt; 1 year.&#xD;
&#xD;
         20. Chronic long-term requirement for NSAIDs (high dose) or COX2 inhibitors, with the&#xD;
             exception of aspirin at doses used for CV prophylaxis (≤325 mg o.d.).&#xD;
&#xD;
         21. Any surgical or medical condition which might significantly alter the absorption,&#xD;
             distribution, metabolism, or excretion of study drugs&#xD;
&#xD;
         22. Subjects get pregnant or will be pregnant within 6 months.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chen-Huan chen, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Taipei Veterans General Hospital, Taiwan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chen-Huan Chen, M.D.</last_name>
    <phone>886228752973</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Taipei Veterans General Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chen-Huan Chen, M.D.</last_name>
      <phone>886228752073</phone>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>July 2010</verification_date>
  <study_first_submitted>February 15, 2011</study_first_submitted>
  <study_first_submitted_qc>February 16, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 17, 2011</study_first_posted>
  <last_update_submitted>February 16, 2011</last_update_submitted>
  <last_update_submitted_qc>February 16, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 17, 2011</last_update_posted>
  <responsible_party>
    <name_title>Chen-Huan Chen</name_title>
    <organization>National YangMing University</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

